321 related articles for article (PubMed ID: 17891368)
1. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.
Chaput N; De Botton S; Obeid M; Apetoh L; Ghiringhelli F; Panaretakis T; Flament C; Zitvogel L; Kroemer G
J Mol Med (Berl); 2007 Oct; 85(10):1069-76. PubMed ID: 17891368
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin exposure dictates the immunogenicity of cancer cell death.
Obeid M; Tesniere A; Ghiringhelli F; Fimia GM; Apetoh L; Perfettini JL; Castedo M; Mignot G; Panaretakis T; Casares N; Métivier D; Larochette N; van Endert P; Ciccosanti F; Piacentini M; Zitvogel L; Kroemer G
Nat Med; 2007 Jan; 13(1):54-61. PubMed ID: 17187072
[TBL] [Abstract][Full Text] [Related]
3. Calreticulin exposure increases cancer immunogenicity.
Clarke C; Smyth MJ
Nat Biotechnol; 2007 Feb; 25(2):192-3. PubMed ID: 17287754
[No Abstract] [Full Text] [Related]
4. Ecto-calreticulin in immunogenic chemotherapy.
Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
6. Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses.
Wu H; Han Y; Qin Y; Cao C; Xia Y; Liu C; Wang Y
Oncol Rep; 2013 Feb; 29(2):529-34. PubMed ID: 23166014
[TBL] [Abstract][Full Text] [Related]
7. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
8. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic.
Obeid M; Panaretakis T; Tesniere A; Joza N; Tufi R; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cancer Res; 2007 Sep; 67(17):7941-4. PubMed ID: 17804698
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Hodge JW; Garnett CT; Farsaci B; Palena C; Tsang KY; Ferrone S; Gameiro SR
Int J Cancer; 2013 Aug; 133(3):624-36. PubMed ID: 23364915
[TBL] [Abstract][Full Text] [Related]
11. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.
Panaretakis T; Joza N; Modjtahedi N; Tesniere A; Vitale I; Durchschlag M; Fimia GM; Kepp O; Piacentini M; Froehlich KU; van Endert P; Zitvogel L; Madeo F; Kroemer G
Cell Death Differ; 2008 Sep; 15(9):1499-509. PubMed ID: 18464797
[TBL] [Abstract][Full Text] [Related]
12. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin.
Obeid M
J Immunol; 2008 Aug; 181(4):2533-43. PubMed ID: 18684944
[TBL] [Abstract][Full Text] [Related]
13. A 'good death' for tumor immunology.
Storkus WJ; Falo LD
Nat Med; 2007 Jan; 13(1):28-30. PubMed ID: 17206130
[No Abstract] [Full Text] [Related]
14. The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure.
Molinari R; D'Eliseo D; Manzi L; Zolla L; Velotti F; Merendino N
Cancer Immunol Immunother; 2011 Oct; 60(10):1503-7. PubMed ID: 21779875
[TBL] [Abstract][Full Text] [Related]
15. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.
Hannani D; Locher C; Yamazaki T; Colin-Minard V; Vetizou M; Aymeric L; Viaud S; Sanchez D; Smyth MJ; Bruhns P; Kroemer G; Zitvogel L
Cell Death Differ; 2014 Jan; 21(1):50-8. PubMed ID: 23744294
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
Fredly H; Ersvær E; Gjertsen BT; Bruserud O
Oncol Rep; 2011 Jun; 25(6):1549-56. PubMed ID: 21431284
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.
Zitvogel L; Kepp O; Senovilla L; Menger L; Chaput N; Kroemer G
Clin Cancer Res; 2010 Jun; 16(12):3100-4. PubMed ID: 20421432
[TBL] [Abstract][Full Text] [Related]
18. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.
Graner MW; Romanoski A; Katsanis E
Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202
[TBL] [Abstract][Full Text] [Related]
19. The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells.
Colangelo T; Polcaro G; Ziccardi P; Muccillo L; Galgani M; Pucci B; Milone MR; Budillon A; Santopaolo M; Mazzoccoli G; Matarese G; Sabatino L; Colantuoni V
Cell Death Dis; 2016 Feb; 7(2):e2108. PubMed ID: 26913599
[TBL] [Abstract][Full Text] [Related]
20. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.
Wemeau M; Kepp O; Tesnière A; Panaretakis T; Flament C; De Botton S; Zitvogel L; Kroemer G; Chaput N
Cell Death Dis; 2010 Dec; 1(12):e104. PubMed ID: 21368877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
